SIGN 142: Management of osteoporosis and the prevention of fragility fractures

Update report

<table>
<thead>
<tr>
<th>Date</th>
<th>Update request</th>
<th>Decision</th>
<th>Status</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 Nov 2020</td>
<td>No recommendations for the use of romosozumab were included in the update published in June 2020, as advice was awaited from the Scottish Medicines Consortium. It was accepted for use in NHSScotland in November 2020.</td>
<td>Agreed</td>
<td>Update published January 2021</td>
<td>Recommendations on the use of romosozumab in postmenopausal women added to section 6.4.9.</td>
</tr>
</tbody>
</table>
| 6 June 2018 | The recommendation to update the guideline was ratified by the Guideline Programme Advisory Group on 6 June 2018. The 2018 three-year scoping report was submitted to the Guideline Programme and Advisory group with the recommendation for an update to the guideline to incorporate new evidence in the following areas:  
  - SCOOP screening tool  
  - safety of denosumab  
  - new pharmacological therapies (abaloparatide, bazedoxifene, teriparatide, romosozumab)  
  - vitamin D supplementation  
  - removal of the sections on cyclical etidronate. | Agreed    | Update published June 2020    | The update includes new evidence on:  
  - human immunodeficiency virus as a risk factor  
  - targeting treatment through population screening  
  - the use of pharmacological therapies: zoledronic acid, denosumab, parathyroid hormone, romosozumab and calcium and vitamin D supplementation.  
  Recommendations for use of risedronate and zoledronic acid in men have also been added.  
  Evidence on abaloparatide and bazedoxifene was not reviewed as it was still subject to approval from the European Medicines Agency. |